SCHEMBL7086833

SCHEMBL7086833

OC(CCl)COc1ccc(Cc2ccc(OCC(O)CCl)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.55
BACE1 P56817 2/20 0.51
MAPK1 P28482 1/20 0.46
MAPT P10636 3/20 0.46
HTT P42858 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CACNA1G O43497 1/20 0.45
KCNH2 Q12809 1/20 0.45
PRMT5 O14744 1/20 0.45
WDR77 Q9BQA1 1/20 0.45
LMNA P02545 1/20 0.44
POLB P06746 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
ADRB2 P07550 2/20 0.44
ADRB1 P08588 2/20 0.44
ADRB3 P13945 2/20 0.44
S1PR1 P21453 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CYP1A2 P05177 1/20 0.42
ATM Q13315 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19677511 1.00 AR (0.55) ARBACE1MAPK1MAPTHTT
SCHEMBL19677510 1.00 AR (0.55) ARBACE1MAPK1MAPTHTT
SCHEMBL19001619 0.92 AR (0.52) ARBACE1MAPK1MAPTHTT
SCHEMBL12267199 0.90 AR (0.51) ARBACE1MAPTLMNAPOLB
SCHEMBL7090393 0.90 AR (0.64) ARMAPK1MAPTHTTSMN1; SMN2
SCHEMBL12314967 0.87 AR (0.49) ARBACE1MAPK1MAPTHTT
SCHEMBL24948597 0.85 AR (0.56) ARMAPK1MAPTHTTSMN1; SMN2
SCHEMBL12517404 0.84 AR (0.58) ARMAPK1MAPTHTTSMN1; SMN2
SCHEMBL7088414 0.84 AR (0.58) ARMAPTHTTSMN1; SMN2LMNA
SCHEMBL13190962 0.84 BACE1 (0.43) ARBACE1MAPK1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119688860-A Method for simultaneously detecting bisphenol diglycidyl ether and p-phenylenediamine antioxidants 中山大学 2025-03-25 CN claimed
CN-119438427-A Method for simultaneously detecting 27 bisphenol compounds in dairy products 重庆市计量质量检测研究院 2025-02-14 CN claimed
CN-114755316-B Method for screening dangerous substances in food contact material and application 广州质量监督检测研究院 2024-02-27 CN claimed
CN-114755316-A Method for screening dangerous substances in food contact material and application 广州质量监督检测研究院 2022-07-15 CN claimed
US-20030149219-A1 Process for manufacturing a hydroxyester derivative intermediate and epoxy resins prepared therefrom BORIACK CLINTON J (US) 2003-08-07 US claimed
US-6534621-B2 Epoxidizing an alpha-halohydrin intermediate produced from an in situ halide substitution-deesterification of an alpha-hydroxy ester derivative DOW GLOBAL TECHNOLOGIES INC. 2003-03-18 US claimed
US-20020045707-A1 Process for manufacturing a hydroxyester derivative intermediate and epoxy resins prepared therefrom DOW GLOBAL TECHNOLOGIES INC. 2002-04-18 US claimed
CN-119688860-A Method for simultaneously detecting bisphenol diglycidyl ether and p-phenylenediamine antioxidants 中山大学 2025-03-25 CN disclosed
CN-119438427-A Method for simultaneously detecting 27 bisphenol compounds in dairy products 重庆市计量质量检测研究院 2025-02-14 CN disclosed
CN-114755316-B Method for screening dangerous substances in food contact material and application 广州质量监督检测研究院 2024-02-27 CN disclosed
US-11760892-B2 Aqueous pigment dispersions HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) 2023-09-19 US disclosed
US-11760892-B2 Aqueous pigment dispersions HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) 2023-09-19 US disclosed
CN-114755316-A Method for screening dangerous substances in food contact material and application 广州质量监督检测研究院 2022-07-15 CN disclosed
US-20130245129-A1 DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2013-09-19 US disclosed
US-20110230556-A1 Diglycidic Ether Derivative Therapeutics and Methods for Their Use THE UNITED STATES GOVERNMENT 2011-09-22 US disclosed
US-20110230556-A1 Diglycidic Ether Derivative Therapeutics and Methods for Their Use THE UNITED STATES GOVERNMENT 2011-09-22 US disclosed
WO-2010000066-A1 DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) 2010-01-07 WO disclosed
US-20030149219-A1 Process for manufacturing a hydroxyester derivative intermediate and epoxy resins prepared therefrom BORIACK CLINTON J (US) 2003-08-07 US disclosed
US-6534621-B2 Epoxidizing an alpha-halohydrin intermediate produced from an in situ halide substitution-deesterification of an alpha-hydroxy ester derivative DOW GLOBAL TECHNOLOGIES INC. 2003-03-18 US disclosed
US-20020045707-A1 Process for manufacturing a hydroxyester derivative intermediate and epoxy resins prepared therefrom DOW GLOBAL TECHNOLOGIES INC. 2002-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130245129-A1 DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE MAN2B2, UGCG, KLK3 AR 179/4885BACE1 3576/4885MAPK1 2686/4885
US-20110230556-A1 Diglycidic Ether Derivative Therapeutics and Methods for Their Use MAN2B2, KLK3, UGCG AR 125/4885BACE1 3674/4885MAPK1 2347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.